

## DISCLOSURES

ASPHO requires that planners and presenters disclose the existence of any financial or other relationship they have with any ineligible companies (defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients). ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product. The ASPHO Accreditation Subcommittee of the Education Committee reviews all disclosures and potential conflicts of interest as submitted by planners and presenters and mitigates such conflicts to ensure the content of the activity is aligned with the interests of the public and is free from commercial bias.

### Disclaimer

The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.

### Speaker Disclosures

No relevant financial relationships and no discussion of off-label drug use: Michael Anderson, Rachel Bercovitz, Katharine Brock, Meghan Browning, Emily Greengard, Paul Harker-Murray, Jennifer Kesselheim, Prerna Kumar, Marcio Malogolowkin, Elizabeth Mullen, Lauren Pommert, Michael Pulsipher.

No relevant financial relationships; off-label drug use discussed: Karen Effinger, Jason Fangusaro, Elizabeth Fox, Melissa Frei-Jones, Mignon Loh, Taizo Nakano, and Sung-Yun Pai.

Relevant financial relationships and no discussion of off-label drug use: Rachel Brennan-Aileron Therapeutics, INC: Consultant, hourly compensation; Mark Fleming-Ribontx: Consultant, honorarium; Minerva Therapeutics: Consultant, honorarium, Forma therapeutics: Consultant, honorarium; EvolveImmune: Consultant, honorarium; Disc Medicine: Advisory Committee, honorarium; Lindsay Frazier-Decibel therapeutics: Consultant, honorarium; Rachel Grace-Agios: Consultant, Principal Investigator, honorarium, research grant to institution; Novartis: Principal Investigator, research grant to institution; Sanofi: Consultant, honorarium; Sobi: Principal Investigator, research grant to institution; Julia Meade-Alexion: Advisory Board, honorarium; Matthew Oberley-Caris Life Sciences: Executive Medical Director; Jackie Powers-Pharmacosmos LLC: Consultant, honorarium; Women's Health Research Collaborative (WHrC)/The Kinetix Group: Advisory Committee Member, honorarium; Creative Educational Concepts, LLC: Speaker, honorarium; Kelly Walkovich-X4 Pharmaceuticals: Principal Investigator, research grant to institution, Advisory Board, honorarium; Sobi Pharmaceuticals: Advisory Board, honorarium; Pharming Group: Advisory Board, honorarium; AstraZeneca, PLC: Advisory Board, honorarium; Guy Young-Apcintex: Consultant, honorarium; BioMarin: Consultant, honorarium; Genentech/Roche: Consultant, honorarium; Hema Bilogics/LFB: Consultant, honorarium; Novo Nordisk: Consultant, honorarium; Octapharma: Consultant, honorarium; Pfizer: Consultant, honorarium; Sanofi Genzyme: Consultant, honorarium; Spark: Consultant, honorarium; Takeda: Consultant, honorarium; Genentech/Roche: Principal Investigator, research grant to institution; Grifols: Principal Investigator, research grant to institution; Takeda: Principal Investigator, research grant to institution.

Relevant financial relationships; off-label drug use discussed: Denise Adams-Novartis: Consultant, honorarium, Balderis: Consultant, honorarium; Up to Date: Author, honorarium; Kenneth McClain-SOBI Corporation: Medical Advisory Panel, honorarium; Cindy Neunert-Dova: Advisory Board, honorarium; Novartis: Advisory Board, honorarium; Johnson & Johnson: Consultant, honorarium; Sarah O'Brien-Bristol Myers Squibb: Principal Investigator, research grant to institution.

### Review Course Committee Disclosures

No relevant financial relationships: Anthony Audino, Ibrahim Ahmed, Stewart Goldman, Amanda Graul-Conroy, Paul Harker-Murray, Michael Jeng, Sajad Khazal, Julie Krystal, Devang Pastakia, Susmita Sarangi.

Relevant financial relationships: Jonathan Fish-Alexion: Data Monitoring Committee, honorarium; Daiichi Sankyo: Data Monitoring Committee, honorarium; Alex George-Global Blood Therapeutics: Speakers Bureau, honorarium; Wolters-Kluwer: Book Chapters, royalties; Forma Therapeutics: Principal Investigator, research

grant to institution; Agios Therapeutics: Advisory Board, honorarium; Julia Meade-Alexion: Advisory Board, honorarium; Cindy Neunert-Dova: Advisory Board, honorarium; Novartis: Advisory Board, honorarium; Johnson & Johnson: Consultant, honorarium.

### **Accreditation Subcommittee**

No relevant financial relationships: Erica Friehling, Chandrika Gowda, Mary-Jane Hogan, Karen Lewing, Kate Mazur.

### **Staff**

No relevant financial relationships: Cassie McGarigle, Ryan Wilkinson.